Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shows promise for painful skin condition

NCT ID NCT04856930

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a drug called imsidolimab (ANB019) in 149 people with hidradenitis suppurativa, a chronic skin condition causing painful abscesses and nodules. Participants received either the drug or a placebo to see if it could reduce the number of inflamed lesions. The study is complete, and results will show whether this antibody approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
imsidolimab (ANB019), a lab-made antibody
What this could lead to
If it works, this could point toward a new treatment option for hidradenitis suppurativa, reducing painful abscesses and nodules.
What could go wrong
This is a mid-stage trial with only 149 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

149 people

The number who actually took part.

Started

Jul 2021

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinically confirmed diagnosis of active HS with a disease duration of greater than or equal to (≥) 6 months before Day 1. 2. HS lesions present in at least 2 distinct anatomical areas. 3. Total Abscess and inflammatory nodule (AN) count ≥ 5. 4. Draining fistulas less than or equal to (≤) 20. 5. Stable HS for at least 6 weeks prior to Day 1 visit. Exclusion Criteria: 1\. Concomitant dermatological or medical conditions that may interfere with the Investigators' ability to evaluate the participant's response to therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Site 10-101

    Fort Gratiot, Michigan, 48059, United States

  • Site 10-102

    Sacramento, California, 95817, United States

  • Site 10-103

    Portsmouth, New Hampshire, 03801, United States

  • Site 10-104

    Fountain Valley, California, 92708, United States

  • Site 10-105

    Norfolk, Virginia, 23502, United States

  • Site 10-106

    Spokane, Washington, 99202, United States

  • Site 10-107

    Largo, Florida, 33770, United States

  • Site 10-108

    Birmingham, Alabama, 35224, United States

  • Site 10-109

    Coral Gables, Florida, 33134, United States

  • Site 10-110

    Sandy Springs, Georgia, 30328, United States

  • Site 10-111

    Tampa, Florida, 33607, United States

  • Site 10-112

    Pflugerville, Texas, 78660, United States

  • Site 10-113

    Greenville, South Carolina, 29615, United States

  • Site 10-115

    Warwick, Rhode Island, 02886, United States

  • Site 10-117

    San Antonio, Texas, 78213, United States

  • Site 10-118

    Houston, Texas, 77056, United States

  • Site 10-119

    Northridge, California, 91324, United States

  • Site 11-101

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Site 11-102

    Markham, Ontario, L3P 1X3, Canada

  • Site 11-103

    Cobourg, Ontario, K9A 0Z4, Canada

  • Site 11-105

    Québec, Quebec, G1N 4V3, Canada

  • Site 11-106

    Calgary, Alberta, T2J7E1, Canada

  • Site 30-103

    Ossy, Silesian Voivodeship, 42-624, Poland

  • Site 30-104

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Site 30-106

    Olsztyn, 10-229, Poland

  • Site 30-107

    Krakow, Malopolska, 30-074, Poland

  • Site 30-108

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Site 30-109

    Lodz, 90-265, Poland

  • Site 59-102

    Tbilisi, 112, Georgia

  • Site 59-103

    Tbilisi, 160, Georgia

  • Site 59-104

    Tbilisi, 159, Georgia

  • Site 59-105

    Tbilisi, 160, Georgia

  • Site 59-106

    Batumi, 6000, Georgia

  • Site 59-107

    Tbilisi, 162, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.